Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

On the efficiency of targeted clinical trials.

Statistics in medicine - 15 Feb 2005

Maitournam A, Simon R

Abstract excerpt

The development of genomics-based technologies is demonstrating that many common diseases are heterogeneous collections of molecularly distinct entities. Molecularly targeted therapeutics is often effective only for some subsets patients with a conventionally defined disease. We consider the problem of design of phase III randomized clinical trials for the evaluation of a molecularly targeted treatment when there...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Clinical Trials, Phase III as Topic
Share to Genetic Predisposition to Disease
Share to Genotype

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Models, Genetic

Share to Randomized Controlled Trials as Topic

Share to Research Design

Source

Identifiers

PMID: 15551403
DOI: 10.1002/sim.1975

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

On the efficiency of targeted clinical trials.PMID 15551403Read ↗

Approaches to evaluation of treatment effect in randomized clinical trials with genomic subset.Semantic proximity Read ↗

Considerations for Developing Targeted Therapies in Low-Frequency Molecular Subsets of a Disease.Semantic proximity Read ↗

Early phase trial designs and endpoints for targeted therapies in rare genotype subsets.Semantic proximity Read ↗

Computational Phenomapping of Randomized Clinical Trials to Enable Assessment of their Real-world Representativeness and Personalized InferenceSemantic proximity Read ↗

Comparative Effectiveness Research, Genomics-Enabled Personalized Medicine, and Rapid Learning Health Care: A Common BondSemantic proximity Read ↗

Evaluating Many Treatments and Biomarkers in Oncology: A New DesignSemantic proximity Read ↗

Computational Phenomapping of Randomized Clinical Trial Participants to Enable Assessment of Their Real-World Representativeness and Personalized Inference.Semantic proximity Read ↗

An efficient basket trial design.Semantic proximity Read ↗

Randomized clinical trials with biomarkers: design issues.Semantic proximity Read ↗

The Bayesian basket design for genomic variant-driven phase II trials.Semantic proximity Read ↗

Distinguishing rational from irrational applications of pharmacogenetic synergies from the bench to clinical trials.Semantic proximity Read ↗

The R.O.A.D. to clinical trial emulationSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.